Raymond James Financial Inc. Invests $21.84 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Raymond James Financial Inc. bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 456,774 shares of the biopharmaceutical company’s stock, valued at approximately $21,838,000.

Several other institutional investors also recently bought and sold shares of HALO. 2Xideas AG lifted its holdings in Halozyme Therapeutics by 24.1% in the 4th quarter. 2Xideas AG now owns 379,240 shares of the biopharmaceutical company’s stock worth $18,131,000 after purchasing an additional 73,653 shares during the last quarter. Aviva PLC boosted its holdings in shares of Halozyme Therapeutics by 39.3% during the 4th quarter. Aviva PLC now owns 137,413 shares of the biopharmaceutical company’s stock worth $6,570,000 after buying an additional 38,765 shares during the period. Prudential PLC grew its stake in Halozyme Therapeutics by 3.2% in the 4th quarter. Prudential PLC now owns 58,075 shares of the biopharmaceutical company’s stock valued at $2,777,000 after buying an additional 1,813 shares during the last quarter. Bryce Point Capital LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth $607,000. Finally, Huntington National Bank lifted its position in Halozyme Therapeutics by 68.2% during the 4th quarter. Huntington National Bank now owns 3,180 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 1,289 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HALO shares. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Benchmark reissued a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $58.79 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $66.00. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a market cap of $7.26 billion, a P/E ratio of 17.14, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The firm’s 50-day simple moving average is $60.42 and its 200-day simple moving average is $55.02.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.